Pharmaceutical company
CorMedix announced that it has been granted a patent from the European Patent
Office for Neutrolin, its low heparin catheter lock solution. Sometimes called
“the Prosl patent,” the solution maintains patency and prevents infection in a
hemodialysis catheter. CorMedix is the exclusive global licensee of European
Patent EP 1 814 562 B1, which was granted on Jan. 8.
This issuance of the Prosl
patent adds significantly to the company’s intellectual property portfolio in
the European Union. The patent will strengthen CorMedix’s ability to compete
with its catheter lock solutions and help raise Europe’s standard of care for
catheters.
CorMedix is a pharmaceutical
company focused on developing and commercializing therapeutic products for
preventing and treating cardio-renal and infectious disease. The company’s
first commercial product is Neutrolin, which is a catheter lock solution that
prevents catheter-related bloodstream infections and maintains catheter patency
in tunneled, cuffed, central venous catheters that are used for vascular access
in hemodialysis patients.
For more information, visit
www.cormedix.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
